Skip to Content

Demant A/S DEMANT

Morningstar Rating
DKK 338.20 +11.60 (3.55%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Demant Sees Strong Recovery in Hearing but Continuing Weakness in Communications

Demant benefits from favourable trends, including an ageing population, increasing noise pollution, fairly low penetration rates in the developed world, and virtually untapped patient populations in emerging markets such as China where Demant acquired the retail chain ShengWang in June 2022. Demant's broad product offerings should allow the company to capitalize on these trends, while its strong brand and superior technological know-how should yield market share gains. After selling its implant business, Demant is in a better position to focus its efforts and maintain its top-tier positioning in the market.

Price vs Fair Value

DEMANT is trading at a 15% premium.
Price
DKK 322.80
Fair Value
DKK 135.00
Uncertainty
Medium
1-Star Price
DKK 366.00
5-Star Price
DKK 545.00
Economic Moat
Chxmkw
Capital Allocation
Ynjjgxs

Bulls Say, Bears Say

Bulls

Approximately 16% of the world's population suffers from mild to severe hearing loss, and this is expected to grow to 20% during the next decade. Even in developed countries, hearing aid penetration rates only reach 20% on average.

Bears

The communications segment is struggling in both the gaming and professional lines.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DEMANT is a good fit for your portfolio.

Trading Information

Previous Close Price
DKK 326.60
Day Range
DKK 327.80338.60
52-Week Range
DKK 247.90373.50
Bid/Ask
DKK 338.00 / DKK 338.40
Market Cap
DKK 74.63 Bil
Volume/Avg
179,800 / 286,910

Key Statistics

Price/Earnings (Normalized)
28.53
Price/Sales
3.21
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
1.17%

Company Profile

Demant is a Denmark-based manufacturer and distributor of hearing solutions, such as hearing aid devices and audio diagnostic equipment. More than 80% of the company's sales come from North America and Europe.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Growth
Total Number of Employees
21,623

Competitors

Valuation

Metric
DEMANT
GN
SOON
Price/Earnings (Normalized)
28.5332.7121.56
Price/Book Value
7.692.867.26
Price/Sales
3.211.444.22
Price/Cash Flow
16.6411.8819.94
Price/Earnings
DEMANT
GN
SOON

Financial Strength

Metric
DEMANT
GN
SOON
Quick Ratio
0.840.480.76
Current Ratio
1.370.651.29
Interest Coverage
6.911.8629.18
Quick Ratio
DEMANT
GN
SOON

Profitability

Metric
DEMANT
GN
SOON
Return on Assets (Normalized)
8.40%0.30%11.96%
Return on Equity (Normalized)
28.27%1.10%30.61%
Return on Invested Capital (Normalized)
12.19%1.28%22.85%
Return on Assets
DEMANT
GN
SOON
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ABT
Abbott LaboratoriesPcpvclxlCwqrqzc$185.4 Bil
SYK
Stryker CorpKwrnvrydyTjyhg$127.7 Bil
BSX
Boston Scientific CorpStzylhrlYssqnd$107.6 Bil
MDT
Medtronic PLCZtvxdqtgwMsdmmpy$105.9 Bil
DXCM
DexCom IncJpczlyrtjmChj$54.7 Bil
EW
Edwards Lifesciences CorpGxqxnpzxptCytqkvg$52.0 Bil
ZBH
Zimmer Biomet Holdings IncJryjhzkzdKpd$24.6 Bil
ALGN
Align Technology IncBlqtfkvdLzkvbw$23.4 Bil
PHG
Koninklijke Philips NV ADRPdgszrtnHnfbq$18.7 Bil
PODD
Insulet CorpTgvfsdjtygGxlbmj$11.6 Bil

Sponsor Center